An allogeneic stem cell therapy under investigation to prevent gastrointestinal bleeding in patients with end-stage heart failure (HF) with reduced ejection fraction (HFrEF) who have had a left ventricular assist device (LVAD) implanted.
An allogeneic stem cell therapy under investigation to prevent gastrointestinal bleeding in patients with end-stage heart failure (HF) with reduced ejection fraction (HFrEF) who have had a left ventricular assist device (LVAD) implanted.